Investigation Report on Chinese Atorvastatin Market 2021-2025

$2,600$3,900

CRI’s market research shows that sales of Atorvastatin began to decline in 2019, and the CAGR from 2016 to 2020 is approximately -0.92%. The main reason is that retail pharmacies have taken more Atorvastatin sales after 2019, which causes the sales decline in sample hospitals.

Clear
SKU: 2104467 Category: Tags: ,

Description

Atorvastatin is a common drug used to lower blood cholesterol levels. Its original drug, Lipitor (developed by Pfizer Inc), entered the Chinese market in 1999. In addition to Pfizer, the other Atorvastatin manufacturers in the Chinese market are Lepu Pharmaceutical, Jialin Pharmaceutical, Qilu Pharmaceutical (Hainan) and Fujian Dawnrays.

CRI’s market research shows that sales of Atorvastatin began to decline in 2019, and the CAGR from 2016 to 2020 is approximately -0.92%. The main reason is that retail pharmacies have taken more Atorvastatin sales after 2019, which causes the sales decline in sample hospitals. Since thfe research data is based on medications used in sample hospitals, the result cannot indicate that Atorvastatin is unpopular in the Chinese market. The sales revenue in 2020 is around CNY0.82 billion, though it dropped about 58% compared to 2019 due to the lost sales and COVID-19 epidemic.

CRI concludes that the Chinese Atorvastatin market will still have a growth trend in the short run. The sales of Atorvastatin will recover due to the improvement of the epidemic situation. In addition, sales will increase as the market expands. The expansion of the market is based on the increase of consumers. With the implementation of the “4+7” policy (a plan for centralized purchasing), the price of Atorvastatin should continue to fall. As a result, except for the patients with high cholesterol, patients with other indications, such as patients with cardiovascular-related diseases may become the target of the drug.

Topics Covered:
-The impact of COVID-19 on China’s atorvastatin market
– Sales value and volume of China’s atorvastatin 2016-2020
– Competitive landscape of China’s atorvastatin market
– Prices of atorvastatin in China
– Prices of atorvastatin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s atorvastatin market
– Prospect of China’s atorvastatin market from 2021 to 2025

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Atorvastatin
1.1 Indications for Atorvastatin
1.2 Development of Atorvastatin in China
1.3 Governmental Approval of Atorvastatin in China
1.4 The Impact of COVID-19 on Atorvastatin sales in China

2 Sales of Atorvastatin in China, 2016-2020
2.1 Sales Value of Atorvastatin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Atorvastatin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Atorvastatin by Dosage Form in China, 2016-2020
2.3.1 Tablet
2.3.2 Capsule
2.3.3 Dispersible tablet

3 Analysis of Major Atorvastatin Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Atorvastatin Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Pfizer Inc
3.2.1 Enterprise Profile
3.2.2 Sales of LIPITOR (Pfizer’s Atorvastatin) in China
3.3 Lepu Pharmaceutical Tech. Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Youliping (Lepu’s Atorvastatin) in China
3.4 Jialin Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of ALE (Jialin’s Atorvastatin) in China
3.5 Qilu Pharmaceutical (Hainan) Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Meidaxin (Qilu’s Atorvastatin) in China
3.6 Fujian Dawnrays Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Anweining/Shumaitong (Fujian Dawnrays’ Atorvastatin) in China

4 Prices of Atorvastatin for Different Manufacturers in China, 2020-2021
4.1 Pfizer Inc (LIPITOR)
4.2 Lepu Pharmaceutical Tech. Co., Ltd. (Youliping)
4.3 Jialin Pharmaceutical Co., Ltd. (ALE)
4.4 Qilu Pharmaceutical (Hainan) Co., Ltd. (Meidaxin)
4.5 Fujian Dawnrays Pharmaceutical Co., Ltd. (Anweining/Shumaitong)

5 Prospect of Chinese Atorvastatin drug Market, 2021-2025
5.1 Influential Factors of Chinese Atorvastatin Market Development
5.1.1 The Impact of COVID-19 on Chinese Atorvastatin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Atorvastatin Registration in China
Chart Sales Value of Atorvastatin over the World
Chart Sales Value of Atorvastatin in China, 2016-2020
Chart Sales Value of Atorvastatin in China by Regions, 2016-2020
Chart Sales Volume of Atorvastatin in China, 2016-2020
Chart Sales Volume of Atorvastatin in China by Regions, 2016-2020
Chart Sales Value of Atorvastatin Tablet in China, 2016-2020
Chart Sales Volume of Atorvastatin Tablet in China, 2016-2020
Chart Sales Value of Atorvastatin Capsule in China, 2016-2020
Chart Sales Volume of Atorvastatin Capsule in China, 2016-2020
Chart Sales Value of Atorvastatin Dispersible tablet in China, 2016-2020
Chart Sales Volume of Atorvastatin Dispersible tablet in China, 2016-2020
Chart Market Share by Sales Value of Top Atorvastatin Manufacturers in China, 2016-2020
Chart Sales Value and Volume of LIPITOR in China, 2016-2020
Chart Sales Value and Volume of Youliping in China, 2016-2020
Chart Sales Value and Volume of ALE in China, 2016-2020
Chart Sales Value and Volume of Meidaxin, 2016-2020
Chart Sales Value and Volume of Anweining/Shumaitong, 2016-2020
Chart Referential Prices of LIPITOR in China, 2020-2021
Chart Referential Prices of Youliping in China, 2020-2021
Chart Referential Prices of ALE in China, 2020-2021
Chart Referential Prices Meidaxin in China, 2020-2021
Chart Referential Prices Anweining/Shumaitong in China, 2020-2021
Chart Forecast on Sales Value of Atorvastatin in China, 2021-2025
Chart Forecast on Sales Volume of Atorvastatin in China, 2021-2025